6 O
ADVERSE O
REACTIONS O
Clinically O
significant O
adverse O
reactions O
that O
appear O
in O
other O
sections O
of O
the O
labeling O
include O
: O
* O
Hypocortisolism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hyperglycemia B-OSE_Labeled_AE
and O
Diabetes B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Bradycardia B-OSE_Labeled_AE
and O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Liver B-OSE_Labeled_AE
Test I-OSE_Labeled_AE
Elevations I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Cholelithiasis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Pituitary B-OSE_Labeled_AE
Hormone I-OSE_Labeled_AE
Deficiency I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
occurring O
in O
> O
= O
20 O
% O
of O
patients O
are O
diarrhea O
, O
nausea O
, O
hyperglycemia O
, O
cholelithiasis O
, O
headache O
, O
abdominal O
pain O
, O
fatigue O
, O
and O
diabetes O
mellitus O
( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Novartis O
Pharmaceuticals O
Corporation O
at O
1-888-669-6682 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

A O
total O
of O
162 O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
were O
exposed O
to O
SIGNIFOR O
in O
the O
Phase O
III O
study O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

At O
study O
entry O
, O
patients O
were O
randomized O
to O
receive O
twice O
a O
day O
( O
b.i.d O
. O
) O

doses O
of O
either O
0.6 O
mg O
or O
0.9 O
mg O
of O
SIGNIFOR O
given O
subcutaneously O
. O

The O
mean O
age O
of O
patients O
was O
approximately O
40 O
years O
old O
with O
a O
predominance O
of O
female O
patients O
( O
78 O
% O
) O
. O

The O
majority O
of O
the O
patients O
had O
persistent O
or O
recurrent O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
83 O
% O
) O
and O
few O
patients O
( O
< O
= O
5 O
% O
) O
in O
either O
treatment O
group O
had O
received O
previous O
pituitary O
irradiation O
. O

The O
median O
exposure O
to O
the O
treatment O
was O
10.4 O
months O
( O
0.03-37.8 O
) O
with O
68 O
% O
of O
patients O
having O
at O
least O
six-months O
exposure O
. O

In O
the O
Phase O
III O
trial O
, O
adverse O
reactions O
were O
reported O
in O
98 O
% O
of O
patients O
. O

The O
most O
common O
adverse O
reactions O
( O
frequency O
> O
= O
20 O
% O
in O
either O
group O
) O
were O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
cholelithiasis B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
and O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
. O

There O
were O
no O
deaths O
during O
the O
study O
. O

Serious O
adverse O
events O
were O
reported O
in O
25 O
% O
of O
patients O
. O

Adverse O
events O
leading O
to O
study O
discontinuation O
were O
reported O
in O
17 O
% O
of O
patients O
. O

Adverse O
reactions O
with O
an O
overall O
frequency O
higher O
than O
5 O
% O
are O
presented O
in O
Table O
1 O
by O
randomized O
dose O
group O
and O
overall O
. O

Adverse O
reactions O
are O
ranked O
by O
frequency O
, O
with O
the O
most O
frequent O
reactions O
listed O
first O
. O

Table O
1 O
- O
Adverse O
reactions O
[ O
n O
( O
% O
) O
] O
with O
an O
overall O
frequency O
of O
more O
than O
5 O
% O
in O
the O
combined O
dose O
group O
in O
the O
Phase O
III O
study O
in O
Cushing O
's O
disease O
patients O
SIGNIFOR0.6 O
mg O
bidN=82 O
SIGNIFOR0.9 O
mg O
bidN=80 O
OverallN=162 O
Diarrhea B-OSE_Labeled_AE
48 O
( O
59 O
) O
46 O
( O
58 O
) O
94 O
( O
58 O
) O
Nausea B-OSE_Labeled_AE
38 O
( O
46 O
) O
46 O
( O
58 O
) O
84 O
( O
52 O
) O
Hyperglycemia B-OSE_Labeled_AE
31 O
( O
38 O
) O
34 O
( O
43 O
) O
65 O
( O
40 O
) O
Cholelithiasis B-OSE_Labeled_AE
25 O
( O
30 O
) O
24 O
( O
30 O
) O
49 O
( O
30 O
) O
Headache B-OSE_Labeled_AE
23 O
( O
28 O
) O
23 O
( O
29 O
) O
46 O
( O
28 O
) O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
19 O
( O
23 O
) O
20 O
( O
25 O
) O
39 O
( O
24 O
) O
Fatigue B-OSE_Labeled_AE
12 O
( O
15 O
) O
19 O
( O
24 O
) O
31 O
( O
19 O
) O
Diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
13 O
( O
16 O
) O
16 O
( O
20 O
) O
29 O
( O
18 O
) O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
14 O
( O
17 O
) O
14 O
( O
18 O
) O
28 O
( O
17 O
) O
Nasopharyngitis B-OSE_Labeled_AE
10 O
( O
12 O
) O
11 O
( O
14 O
) O
21 O
( O
13 O
) O
Alopecia B-OSE_Labeled_AE
10 O
( O
12 O
) O
10 O
( O
13 O
) O
20 O
( O
12 O
) O
Asthenia B-OSE_Labeled_AE
13 O
( O
16 O
) O
5 O
( O
6 O
) O
18 O
( O
11 O
) O
Glycosylated B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
10 O
( O
12 O
) O
8 O
( O
10 O
) O
18 O
( O
11 O
) O
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
11 O
( O
13 O
) O
6 O
( O
8 O
) O
17 O
( O
10 O
) O
Gamma B-OSE_Labeled_AE
- I-OSE_Labeled_AE
glutamyl I-OSE_Labeled_AE
transferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
10 O
( O
12 O
) O
7 O
( O
9 O
) O
17 O
( O
10 O
) O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
9 O
( O
11 O
) O
8 O
( O
10 O
) O
17 O
( O
10 O
) O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
10 O
( O
12 O
) O
6 O
( O
8 O
) O
16 O
( O
10 O
) O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
7 O
( O
9 O
) O
9 O
( O
11 O
) O
16 O
( O
10 O
) O
Hypercholesterolemia B-OSE_Labeled_AE
7 O
( O
9 O
) O
9 O
( O
11 O
) O
16 O
( O
10 O
) O
Hypertension B-OSE_Labeled_AE
8 O
( O
10 O
) O
8 O
( O
10 O
) O
16 O
( O
10 O
) O
Dizziness B-OSE_Labeled_AE
8 O
( O
10 O
) O
7 O
( O
9 O
) O
15 O
( O
9 O
) O
Hypoglycemia B-OSE_Labeled_AE
12 O
( O
15 O
) O
3 O
( O
4 O
) O
15 O
( O
9 O
) O
Type B-OSE_Labeled_AE
2 I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
10 O
( O
12 O
) O
5 O
( O
6 O
) O
15 O
( O
9 O
) O
Anxiety B-OSE_Labeled_AE
5 O
( O
6 O
) O
9 O
( O
11 O
) O
14 O
( O
9 O
) O
Influenza B-OSE_Labeled_AE
9 O
( O
11 O
) O
5 O
( O
6 O
) O
14 O
( O
9 O
) O
Insomnia B-OSE_Labeled_AE
3 O
( O
4 O
) O
11 O
( O
14 O
) O
14 O
( O
9 O
) O
Myalgia B-OSE_Labeled_AE
10 O
( O
12 O
) O
4 O
( O
5 O
) O
14 O
( O
9 O
) O
Arthralgia B-OSE_Labeled_AE
5 O
( O
6 O
) O
8 O
( O
10 O
) O
13 O
( O
8 O
) O
Pruritus B-OSE_Labeled_AE
6 O
( O
7 O
) O
7 O
( O
9 O
) O
13 O
( O
8 O
) O
Lipase B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
7 O
( O
9 O
) O
5 O
( O
6 O
) O
12 O
( O
7 O
) O
Constipation B-OSE_Labeled_AE
7 O
( O
9 O
) O
4 O
( O
5 O
) O
11 O
( O
7 O
) O
Hypotension B-OSE_Labeled_AE
5 O
( O
6 O
) O
6 O
( O
8 O
) O
11 O
( O
7 O
) O
Vomiting B-OSE_Labeled_AE
3 O
( O
4 O
) O
8 O
( O
10 O
) O
11 O
( O
7 O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
4 O
( O
5 O
) O
6 O
( O
8 O
) O
10 O
( O
6 O
) O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
5 O
( O
6 O
) O
5 O
( O
6 O
) O
10 O
( O
6 O
) O
Electrocardiogram B-OSE_Labeled_AE
QT I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
5 O
( O
6 O
) O
5 O
( O
6 O
) O
10 O
( O
6 O
) O
Hypokalemia B-OSE_Labeled_AE
6 O
( O
7 O
) O
4 O
( O
5 O
) O
10 O
( O
6 O
) O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
6 O
( O
7 O
) O
4 O
( O
5 O
) O
10 O
( O
6 O
) O
Sinus B-OSE_Labeled_AE
bradycardia I-OSE_Labeled_AE
8 O
( O
10 O
) O
2 O
( O
3 O
) O
10 O
( O
6 O
) O
Vertigo B-OSE_Labeled_AE
4 O
( O
5 O
) O
6 O
( O
8 O
) O
10 O
( O
6 O
) O
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
4 O
( O
5 O
) O
5 O
( O
6 O
) O
9 O
( O
6 O
) O
Adrenal B-OSE_Labeled_AE
insufficiency I-OSE_Labeled_AE
4 O
( O
5 O
) O
5 O
( O
6 O
) O
9 O
( O
6 O
) O
Aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
6 O
( O
7 O
) O
3 O
( O
4 O
) O
9 O
( O
6 O
) O
Blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
6 O
( O
7 O
) O
3 O
( O
4 O
) O
9 O
( O
6 O
) O
Other O
notable O
adverse O
reactions O
which O
occurred O
with O
a O
frequency O
less O
than O
5 O
% O
were O
: O
anemia B-OSE_Labeled_AE
( O
4 O
% O
) O
; O
blood B-OSE_Labeled_AE
amylase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
2 O
% O
) O
and O
prothrombin B-OSE_Labeled_AE
time I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Gastrointestinal O
Disorders O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
, O
predominantly O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
were O
reported O
frequently O
in O
the O
Phase O
III O
trial O
( O
see O
Table O
1 O
) O
. O

These O
events O
began O
to O
develop O
primarily O
during O
the O
first O
month O
of O
treatment O
with O
SIGNIFOR O
and O
required O
no O
intervention O
. O

Hyperglycemia O
and O
Diabetes O
Hyperglycemia B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
terms I-OSE_Labeled_AE
were O
reported O
frequently O
in O
the O
Phase O
III O
trial O
. O

For O
all O
patients O
, O
these O
terms O
included O
: O
hyperglycemia B-OSE_Labeled_AE
( O
40 O
% O
) O
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
( O
18 O
% O
) O
, O
increased B-OSE_Labeled_AE
HbA I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
( O
11 O
% O
) O
, O
and O
type B-OSE_Labeled_AE
2 I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
( O
9 O
% O
) O
. O

In O
general O
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
FPG I-OSE_Labeled_AE
) O
and O
hemoglobin O
A1c O
( O
HbA1c O
) O
were O
seen O
soon O
after O
initiation O
of O
SIGNIFOR O
and O
were O
sustained O
during O
the O
treatment O
period O
. O

In O
the O
SIGNIFOR O
0.6 O
mg O
group O
, O
mean O
fasting B-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
FPG I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from O
98.6 O
mg/dL O
at O
baseline O
to O
125.1 O
mg/dL O
at O
Month O
6 O
. O

In O
the O
SIGNIFOR O
0.9 O
mg O
group O
, O
mean O
fasting B-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
FPG I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from O
97.0 O
mg/dL O
at O
baseline O
to O
128.0 O
mg/dL O
at O
Month O
6 O
. O

In O
the O
SIGNIFOR O
0.6 O
mg O
group O
, O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from O
5.8 O
% O
at O
baseline O
to O
7.2 O
% O
at O
Month O
6 O
. O

In O
the O
SIGNIFOR O
0.9 O
mg O
group O
, O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from O
5.8 O
% O
at O
baseline O
to O
7.3 O
% O
at O
Month O
6 O
[ O
see O
Warning O
and O
Precautions O
( O
5.2 O
) O
] O
. O

At O
one-month O
follow-up O
visits O
following O
discontinuation O
of O
SIGNIFOR O
, O
mean B-NonOSE_AE
FPG I-NonOSE_AE
and O
HbA1c O
levels I-NonOSE_AE
decreased I-NonOSE_AE
but O
remained O
above O
baseline O
values O
. O

Long-term O
follow-up O
data O
are O
not O
available O
. O

Elevated O
Liver O
Tests O
In O
the O
Phase O
III O
trial O
, O
there O
were O
transient O
mean O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
values O
in O
patients O
treated O
with O
SIGNIFOR O
. O

Mean O
values O
returned O
to O
baseline O
levels O
by O
Month O
4 O
of O
treatment O
. O

The O
elevations O
were O
not O
associated O
with O
clinical O
symptoms O
of O
hepatic B-NonOSE_AE
disease I-NonOSE_AE
. O

In O
the O
clinical O
development O
program O
of O
SIGNIFOR O
, O
there O
were O
4 O
patients O
with O
concurrent O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
greater O
than O
3 O
x O
ULN O
and O
bilirubin O
greater O
than O
2 O
x O
ULN O
: O
one O
patient O
with O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
and O
three O
healthy O
volunteers O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

In O
all O
four O
cases O
, O
the O
elevations O
were O
noted O
within O
the O
first O
10 O
days O
of O
treatment O
. O

In O
all O
of O
these O
cases O
, O
total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
seen O
either O
concomitantly O
or O
preceding O
the O
transaminase B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
. O

The O
patient O
with O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
developed O
jaundice B-OSE_Labeled_AE
. O

All O
four O
cases O
had O
resolution O
of O
the O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
with O
discontinuation O
of O
SIGNIFOR O
. O

Hypocortisolism O
Cases O
of O
hypocortisolism B-OSE_Labeled_AE
were O
reported O
in O
the O
Phase O
III O
study O
in O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
and O
Clinical O
Studies O
( O
14 O
) O
] O
. O

The O
majority O
of O
cases O
were O
manageable O
by O
reducing O
the O
dose O
of O
SIGNIFOR O
and/or O
adding O
low-dose O
, O
short-term O
glucocorticoid O
therapy O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Injection O
Site O
Reactions O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
reported O
in O
17 O
% O
of O
patients O
enrolled O
in O
the O
Phase O
III O
trial O
in O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

The O
events O
were O
most O
frequently O
reported O
as O
local B-OSE_Labeled_AE
pain O
, O
erythema I-OSE_Labeled_AE
, O
hematoma O
, O
hemorrhage O
, O
and O
pruritus O
. O

These O
events O
resolved O
spontaneously O
and O
required O
no O
intervention O
. O

Thyroid O
Function O
Hypothyroidism B-OSE_Labeled_AE
with O
the O
use O
of O
SIGNIFOR O
was O
reported O
for O
seven O
patients O
participating O
in O
the O
Phase O
III O
study O
in O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

All O
seven O
patients O
presented O
with O
a O
TSH B-Not_AE_Candidate
close I-Not_AE_Candidate
to I-Not_AE_Candidate
or I-Not_AE_Candidate
below I-Not_AE_Candidate
the I-Not_AE_Candidate
lower I-Not_AE_Candidate
limit I-Not_AE_Candidate
at O
study O
entry O
which O
precludes O
establishing O
a O
conclusive O
relationship O
between O
the O
adverse O
event O
and O
the O
use O
of O
SIGNIFOR O
. O

Other O
Abnormal O
Laboratory O
Findings O
Asymptomatic O
and O
reversible O
elevations B-OSE_Labeled_AE
in O
lipase I-OSE_Labeled_AE
and O
amylase O
were O
observed O
in O
patients O
receiving O
SIGNIFOR O
in O
clinical O
studies O
. O

Pancreatitis B-OSE_Labeled_AE
is O
a O
potential O
adverse O
reaction O
associated O
with O
the O
use O
of O
somatostatin O
analogs O
due O
to O
the O
association O
between O
cholelithiasis B-NonOSE_AE
and O
acute B-NonOSE_AE
pancreatitis I-NonOSE_AE
. O

For O
hemoglobin O
levels O
, O
mean O
decreases O
that O
remained O
within O
normal O
range O
were O
observed O
. O

Also O
, O
post-baseline O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
PT I-OSE_Labeled_AE
and O
PTT O
were O
noted O
in O
33 O
% O
and O
47 O
% O
of O
patients O
, O
respectively O
. O

The O
PT B-OSE_Labeled_AE
and O
PTT O
elevations I-OSE_Labeled_AE
were O
minimal O
. O

These O
laboratory O
findings O
are O
of O
unclear O
clinical O
significance O
. O

